Naohito Kawasaki

Prof. Naohito Kawasaki

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
STSeiki Tanada
Seiki Tanada
MKMineaki Kabayama
Mineaki Kabayama
NKNaohito Kawasaki
Naohito Kawasaki
TSToru Sakiyama
Toru Sakiyama
TNTakeo Nakamura
Takeo Nakamura
TTTakamichi Tamura
Takamichi Tamura

1 January 2005 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
TTToshimitsu Tokimoto
Toshimitsu Tokimoto
NKNaohito Kawasaki
Naohito Kawasaki
TNTakeo Nakamura
Takeo Nakamura
JAJyunichi Akutagawa
Jyunichi Akutagawa
STSeiki Tanada
Seiki Tanada

1 June 1999 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
STSeiki Tanada
Seiki Tanada
NKNaohito Kawasaki
Naohito Kawasaki
TNTakeo Nakamura
Takeo Nakamura
MAMamiko Araki
Mamiko Araki
MIMasahiko Isomura
Masahiko Isomura

1 October 2002 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
MHMizuho Hirata
Mizuho Hirata
NKNaohito Kawasaki
Naohito Kawasaki
TNTakeo Nakamura
Takeo Nakamura
KMKazuoki Matsumoto
Kazuoki Matsumoto
MKMineaki Kabayama
Mineaki Kabayama
STSeiki Tanada
Seiki Tanada

1 August 2002 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
ANAkio Nakanishi
Akio Nakanishi
MTMotoharu Tamai
Motoharu Tamai
NKNaohito Kawasaki
Naohito Kawasaki
TNTakeo Nakamura
Takeo Nakamura
STSeiki Tanada
Seiki Tanada

1 February 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
NNNoriaki Nagai
Noriaki Nagai
FOFumihiko Ogata
Fumihiko Ogata
HOHiroko Otake
Hiroko Otake
YNYosuke Nakazawa
Yosuke Nakazawa
NKNaohito Kawasaki
Naohito Kawasaki
Purpose: We previously found that ophthalmic formulations containing nanoparticles prepared by a bead mill method lead to an increase in bioavailability in comparison with traditional formulations (solution type). However, the transcorneal penetration pathway for ophthalmic formulations has not been explained yet. In this study, we investigated the mechanism of transcorneal penetration in the application of ophthalmic formulations containing indomethacin nanoparticles (IMC-NPs). Materials and methods: IMC-NPs was prepared by the bead mill method. For the analysis of energy-dependent endocytosis, corneal epithelial (HCE-T) cell monolayers and removed rabbit cornea were thermoregulated at 4°C, where energy-dependent endocytosis is inhibited. In addition, for the analysis of different endocytosis pathways using pharmacological inhibitors, inhibitors of caveolae-mediated endocytosis (54 µM nystatin), clathrin-mediated endocytosis (40 µM dynasore), macropinocytosis (2 µM rottlerin) or phagocytosis (10 µM cytochalasin D) were used. Results: The ophthalmic formulations containing 35–200 nm sized indomethacin nanoparticles were prepared by treatment with a bead mill, and no aggregation or degradation of indomethacin was observed in IMC-NPs. The transcorneal penetration of indomethacin was significantly decreased by the combination of nystatin, dynasore and rottlerin, and the decreased penetration levels were similar to those at 4°C in HCE-T cell monolayers and rabbit cornea. In the in vivo experiments using rabbits, dynasore and rottlerin tended to decrease the transcorneal penetration of indomethacin (area under the drug concentration – time curve in the aqueous humor [AUCAH]), and the AUCAH in the nystatin-treated rabbit was significantly lower than that in non-treatment group. In addition, the AUCAH in rabbit corneas undergoing multi-treatment was obviously lower than that in rabbit corneas treated with each individual endocytosis inhibitor. Conclusion: We found that three energy-dependent endocytosis pathways (clathrin-dependent endocytosis, caveolae-dependent endocytosis and macropinocytosis) are related to the transcorneal penetration of indomethacin nanoparticles. In particular, the caveolae-dependent endocytosis is strongly involved.